The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm
Abstract
There is no accepted standard of care for the chemotherapy treatment of metastatic brain tumors, which has been generally limited to lipophilic alkylators, which may not have efficacy against the tumor that metastasized to the brain. More than 50% of chemotherapy agents are natural product drugs, which are rarely used in the treatment of metastatic brain tumors because they are thought to not cross the blood-brain barrier (BBB). A major protein constituent in the BBB is P-glycoprotein (P-gp), which pumps natural product chemotherapy drugs and toxins out of the CNS. However, P-gp expression in the neovasculature of metastatic brain tumors is similar to the P-gp expression in the neovasculature of the primary, extracranial tumor. In contrast, gliomas have higher P-gp expression in their neovasculature, similar to the greater intrinsic expression of P-gp in normal brain vasculature. This decreased immunohistochemical expression of P-gp in the neovasculature of metastatic tumors, as well as our recent pharmacologic demonstration of increased tissue concentrations of paclitaxel in metastatic brain tumors compared with gliomas, support the idea that the choice of chemotherapy agents should be based on the histologic origin of the metastatic brain tumor and not on the lipophilicity of the drug. Our hypothesis is that metastatic brain tumors from tumors with intrinsically low P-gp expression (eg, lung, melanoma, and untreated breast) may be more permeable to natural product chemotherapy drugs than gliomas. This information could lead to a paradigm shift in the use of natural product drugs for metastatic brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
VEGF enhances angiogenesis and promotes blood–brain barrier leakage in the ischemic brain
Zhang, Z. G., Zhang, L., Jiang, Q., Zhang, R., Davies, K., Powers, C., Bruggen, N. V., & Chopp, M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9369 · Cited by 1,296
Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
Cordon-Cardo, C., O'Brien, J. P., Boccia, J., Casals, D., Bertino, J. R., & Melamed, M. R. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.9.1974900 · Cited by 1,062
Brain metastases: epidemiology and pathophysiology
Gavrilovic, I. T., & Posner, J. B. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-8093-6 · Cited by 975
Distribution of Brain Metastases
Delattre, J. Y., Krol, G., Thaler, H. T., & Posner, J. B. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520310047016 · Cited by 778
Brain metastases: Histology, multiplicity, surgery, and survival
Nussbaum, E. S., Djalilian, H. R., Cho, K. H., & Hall, W. A. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961015)78:8<1781::aid-cncr19>3.0.co;2-u · Cited by 679
Outwitting the Blood-Brain Barrier for Therapeutic Purposes: Osmotic Opening and Other Means
KrolI, R. A., Neuwelt, E. A., & Neuwelt, E. A. (1998) · Neurosurgery · doi:10.1097/00006123-199805000-00082 · Cited by 581
Cited by
Challenges to curing primary brain tumours
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., Adkins, C. E., Roberts, A., Thorsheim, H. R., Gaasch, J. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1564 · Cited by 693
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
Miller, D. S., Bauer, B., & Hartz, A. M. S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07109 · Cited by 392
Brufsky, A. M., Mayer, M., Rugo, H. S., Kaufman, P. A., Tan-Chiu, E., Tripathy, D., Tudor, I. C., Wang, L. I., Brammer, M. G., Shing, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2962 · Cited by 386
Breast cancer brain metastases: biology and new clinical perspectives
Witzel, I., Oliveira-Ferrer, L., Pantel, K., Müller, V., & Wikman, H. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0665-1 · Cited by 300
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282
Sarin, H., Kanevsky, A. S., Wu, H., Brimacombe, K. R., Fung, S. H., Sousa, A. A., Auh, S., Wilson, C. M., Sharma, K., Aronova, M. A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-80 · Cited by 274
Astrocytes Upregulate Survival Genes in Tumor Cells and Induce Protection from Chemotherapy
Kim, S.-J., Kim, J.-S., Park, E. S., Lee, J.-S., Lin, Q., Langley, R. R., Maya, M., He, J., Kim, S.-W., Weihua, Z., et al. (2011) · Neoplasia · doi:10.1593/neo.11112 · Cited by 268
Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0566 · Cited by 168
Li, J., Wu, J., Bao, X., Honea, N., Xie, Y., Kim, S., Sparreboom, A., & Sanai, N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0983 · Cited by 68
“However, it is important to note that given the complex physiology of the BBB permeability affected by active transporters, molecule charge, and binding to plasma protein or brain tissue, contrast enhancement by water-soluble, non-ionic gadolinium agents may not accurately reflect the BBB penetration of lipophilic, ch…”
BackgroundKim, M., Ma, D. J., Calligaris, D., Zhang, S., Feathers, R. W., Vaubel, R. A., Meaux, I., Mladek, A. C., Parrish, K. E., Jin, F., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0600 · Cited by 39
Metadata
- Authors
- Gerstner, E. R., & Fine, R. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-01
- Volume
- 25
- Issue
- 16
- Pages
- 2306-2312
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2095265260
- Cited by
- 265
- References
- 59
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.